Ethical adult stem cells have a proven track record of success. Why, then, asks researcher David Prentice, is the NIH still spending $250 million a year killing embryos?
Published, peer-reviewed clinical trials have shown stem cells have reversed stroke damage years after the injury, helped spinal-cord-injury victims regain lost movement, helped heart attack patients recover, cured sickle cell anemia and reversed a wide range of diseases, including multiple sclerosis, type 1 diabetes and lupus erythematosus.
Advances with ethically sourced adult stem cells have already helped more than 1 million patients, according to a recently published review paper by David Prentice, a research director for the Charlotte Lozier Institute and a former professor of medical and molecular genetics at Indiana University School of Medicine.
He calls adult stem cells the true gold standard of regenerative medicine, while nearly two decades of media hype and the infusion of billions of research dollars on stem cells culled from human embryos have produced exactly zero published reports of validated success in a single patient.
Actually, its probably closer to 2 million patients that have been treated with adult stem cells now, Prentice told the Register. The 1 million figure he cited in his paper is from 2012, and the field of stem-cell research has exploded since then.
The Virginia-based Charlotte Lozier Institute has been trying to raise awareness about the successes of adult stem-cell therapies, against a mainstream media that seems to ignore them while championing more research on embryos. The institute has produced a series of videos featuring patients who have recovered from a wide range of diseases, including some of the most debilitating brain injuries and autoimmune diseases that have become epidemic.
One of the stories they tell is that of Sonia Coontz. She didnt realize she was having a massive stroke in May 2011 because she was only 31 years old at the time. During the day she suffered the stroke, the Long Island dog trainer noticed that different words came out of her mouth than the ones she wanted to speak. By evening, her husband, Peter, noticed that half her face had fallen slack. Later, she was struggling to move her arm and her leg, but she knew she was in real trouble when she tried to call Peter but couldnt say his name.
Doctors told Coontz the stroke damage clearly visible as a large, white mass on her brain scans was irreversible, and she would be severely disabled for life. For two years, this diagnosis proved accurate; Coontz could speak only 20 words, she couldnt move her right arm more than a few inches, her shoulder was in constant pain, and she could not walk more than five minutes without needing a wheelchair. She sank into depression.
Two years after her major stroke, when she was considered well beyond any hope of further recovery, Coontz heard about stem-cell trials at Stanford University. She became one of 18 patients enrolled by neurosurgeon Gary Steinberg to undergo a transplant of bone marrow stem cells directly into her brain, next to the area of her stroke damage.
Almost immediately after the surgery, Coontz was able to raise her paralyzed right arm over her head. Her voice became stronger and her language returned. She now runs, climbs stairs and has had a baby.
He has given me a new life, she said of Steinberg when she presented him the Smithsonian American Ingenuity award for his work in 2017.
Not all of Steinbergs patients experienced as miraculous improvement as Coontz did, but several had clinical improvements, and the clinical trial revolutionized the understanding of the brains potential for post-stroke recovery and the potential of stem cells to induce that recovery. It also spurred on dozens of other researchers looking to help the more than 800,000 annual American stroke victims, as well as those using stem cells to treat traumatic brain injury and neurodegenerative diseases such as Alzheimers and Parkinsons.
Lupus and Multiple Sclerosis
Other stem-cell recipients include Jackie Stollfus, who suffered from lupus erythematosus, an autoimmune disease that has recently become the leading killer of young women in America.
Stollfus immune system had begun attacking her own cells, and she was suffering from arthritis and kidney failure and was barely able to get out of bed. She miscarried her first baby because of complications of the disease. Stollfus underwent chemotherapy to obliterate her own immune system and then had filtered stem cells from her own marrow transplanted in a clinical trial by Dr. Richard Burt at Northwestern University.
Seven years later, she has no sign of lupus, and she has given birth to two healthy baby girls.
Burts research has also been researching adult stem-cell transplants in patients with multiple sclerosis; and his study published this year, of 103 patients, found that only three of those who underwent stem-cell therapy progressed further into disease compared to 34 of those getting standard treatment. And most stem-cell patients showed clinical improvement compared to most standard patients who deteriorated. In one of his patients, Allison Carr, the therapy appears to have reversed the paralyzing autoimmune disease in its tracks.
For one disease at least, sickle cell anemia, stem-cell therapy has moved beyond clinical trials. A 2018 review paper refers to the use of adult stem cells for sickle cell disease (which afflicts 100,000 Americans with severe anemia, pain, strokes and organ failure) as the only curative approach for this disease.
Money Down the Drain
One of the biggest hurdles to moving adult stem-cell research forward is funding. There are reports that patients in Burts trials were paying as much as $100,000 to enroll in the trial. Carr had set up a GoFundMe page.
Prentice thinks that the money still being directed by the National Institutes of Health toward embryo funding could go a long way in moving gold standard stem-cell research into the mainstream. Notwithstanding President Donald Trumps recent appointment of a committee to investigate alternatives to fetal tissue and embryonic stem-cell research, these ethically prohibited methods have so far not produced any changes.
Its really disappointing, said Prentice, pointing to the 2018 NIH funding portfolio, which allots $246 million in federal funds to human embryonic research, about the same as it was under the Obama administration.
Thats about a quarter of a billion dollars for just one year. What could that do if it was redirected to actually treat patients or to get them into clinical trials for actual clinical research? Embryonic stem-cell research is not funding a single clinical trial.
Instead, he said, most of that research will be used to inject the human cells into animals, and much of it will be trying to overcome the biggest bugbear that embryonic stem cells have, which is their tendency to grow into tumors.
The job description of the embryonic stem cell at that point in their life is to grow very rapidly and to be able to form basically all of the cells in the human body, said Prentice. This magical so-called pluripotency is also why they grow cancerous.
In fact, Prentice added, researchers test if they are working with true pluripotent stem cells by first injecting them in mice to see if they generate tumors.
This tumorigenicity has so far been an insurmountable technical challenge of embryo cells. The use of these cells pose ethical problems since they require the killing of living human embryos usually leftovers thawed from the freezers of in vitro fertilization businesses.
Ironically, it is the same problem that researchers ran into doing fetal-tissue transplants. Once the shining star of medical promise, federally funded transplants of tissue from aborted babies into patients entranced some medical researchers for nearly 15 years, but ended disastrously.
Prentice thinks NIHs executive director, Francis Collins, a holdover from the Obama administration, is at least part of the reason for the fixation on embryos as well. Ive met with him. He has a very utilitarian ethics, he said.
From a utilitarian perspective, however, embryo research still doesnt add up.
Quit wasting money, said Prentice, and quit wasting lives: the lives of human embryos and the lives of patients we could be curing.
Register correspondent Celeste McGovern writes from Nova Scotia, Canada.
- Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To... - Azizsalon News - May 21st, 2020
- Georgetown student takes Islamic bioethics research at QF to Washington and wins - Gulf Times - May 21st, 2020
- Dose-dependent functions of SWI/SNF BAF in permitting and inhibiting cell proliferation in vivo - Science Advances - May 21st, 2020
- Human Embryonic Stem Cells (HESC) Market to witness an impressive growth during - News by aeresearch - May 20th, 2020
- Qatar- Georgetown student takes Islamic bioethics research at QF to Washington and wins - MENAFN.COM - May 15th, 2020
- Millions of Human Cells Have Been Grown Inside Mice Embryos - Newsweek - May 14th, 2020
- AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update - Business Wire - May 14th, 2020
- Human Embryonic Stem Cells (HESC) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 14th, 2020
- The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -... - May 14th, 2020
- 2025 Projections: Cell Freezing Media for Cell Therapy Market Report by Type, Application and Regional Outlook - AlgosOnline - May 14th, 2020
- Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS) - The... - May 14th, 2020
- Strides in Medical Tourism Market Key Driver of Low-cost Patient Care in Globalized Healthcare Systems, Notes TMR - Stockhouse - May 14th, 2020
- Uses and Abuses of Scientific Consensus - National Review - May 13th, 2020
- Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy - Business Wire - May 13th, 2020
- COVID-19 Impact on STEM CELL THERAPY MARKET 2020 TO 2027-EXPANDING WORLDWIDE WITH TOP PLAYERS FUTURE BUSINESS SCOPE AND INVESTMENT ANALYSIS REPORT -... - May 13th, 2020
- Human Embryonic Stem Cells (HESC) Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty - May 10th, 2020
- Louis Bacon Is Having The Time Of His Life - Dealbreaker - May 10th, 2020
- Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy - Yahoo Finance - May 10th, 2020
- Human Embryonic Stem Cells, Germ Cells, and Cell-Derived ... - May 7th, 2020
- Inside the twisted world of 'rapist' designer Peter Nygard: book - The Loppy - May 4th, 2020
- Lack of investment is the biggest challenge in stem cell research - Express Healthcare - May 2nd, 2020
- AgeX Therapeutics: Revolutionary Potential But Extremely Early - Seeking Alpha - April 30th, 2020
- Human Embryonic Stem Cells (HESC) Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald - April 27th, 2020
- Role of MyHC-embryonic protein in muscle development and disease - Tech Explorist - April 27th, 2020
- The Republicans who were once so pro-life they fought over one woman on life support now want to sacrifice grandma for the economy - The Independent - April 26th, 2020
- Sustainably Yours: The importance of understanding and trusting in Science - The Phuket News - April 26th, 2020
- Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify's iPSC- and ESC-derived regulatory T cells - SelectScience - April 24th, 2020
- Stem Cell Therapy Market Research Outlook, Recent Trends and Growth Forecast 2020-2025 - Cole of Duty - April 24th, 2020
- Mogrify and Sangamo in license agreement for 'off-the-shelf' CAR-Treg - BioPharma-Reporter.com - April 23rd, 2020
- Lozier praises promising, and ethical, blindness study - OneNewsNow - April 23rd, 2020
- A potent CBP/p300-Snail interaction inhibitor suppresses tumor growth and metastasis in wild-type p53-expressing cancer - Science Advances - April 23rd, 2020
- PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis - Science Advances - April 21st, 2020
- Cyborg computer chips will get their brain from human neurons - SYFY WIRE - April 11th, 2020
- Stem Cells Market Expected to Boost the Global Industry Growth in the Near Future - Germany English News - April 11th, 2020
- Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance - Science Advances - April 11th, 2020
- Turning Back the Clock on Aging Cells - The New York Times - March 31st, 2020
- A New Way to Study HIV's Impact on the Brain - Global Health News Wire - March 31st, 2020
- Human Embryonic Stem Cell Market Analysis and Forecasts to 2027 By Recent Trends, Developments In Manufacturing Technology And Regional Growth... - March 31st, 2020
- Laboratory model looking at how a HIV infection impacts the brain - Health Europa - March 31st, 2020
- Cell Banking Outsourcing Market With Economic Growth And Five Forces Analysis By 2021 - Lake Shore Gazette - March 30th, 2020
- Global Human Embryonic Stem Cells Market Provides an In-Depth Insight of Sales Analysis, Growth Forecast and Upcoming Trends Opportunities by Types... - March 26th, 2020
- PD-1 Blocker Safe in Childhood Cancers. But Does It Work? - MedPage Today - March 19th, 2020
- YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma - Science Advances - March 19th, 2020
- Can hybrid embryos save the white rhinos from extinction? - Science 101 - March 17th, 2020
- Autologous Stem Cell Based Therapies Market 2020: Potential Growth, Challenges, Attractive Valuation | Key Players: Anterogen, Holostem Advanced... - March 17th, 2020
- Worldwide Cell Therapy Market Projections to 2028 - The Largest Expansion Will Be in Diseases of the Central Nervous System, Cancer and Cardiovascular... - March 15th, 2020
- 22.5% Growth Rate for Synthetic Stem Cells Market by 2028 | Overview, Top Technologies, Key Insights and Company Profiles - News Times - March 15th, 2020
- Single-Cell Analysis of Ovarian Cortex Fails to Find Stem Cells - The Scientist - March 7th, 2020
- Organoids, iPSCs, and advanced cell models: Advancing discovery from basic research to drug discovery - Science Magazine - March 2nd, 2020
- Stem Cell Therapy Market Opportunity Analysis and Industry Forecast up to 2017 2025 - Jewish Life News - March 2nd, 2020
- The very interesting life of the Hydractinia - Jill Lopez - February 28th, 2020
- Intrinsic disorder controls two functionally distinct dimers of the master transcription factor PU.1 - Science Advances - February 22nd, 2020
- Stem Cell Therapy Market: Business Opportunities, Current Trends and Industry Analysis by 2018 2028 - Instant Tech News - February 21st, 2020
- Anatomy of a grant: Ashley Kramer's yearlong journey to finding her doctoral thesis - The South End - February 21st, 2020
- The Challenge of Bioethics to Decision-Making in the UK - Westminster Abbey - February 21st, 2020
- The 411 on Stem Cells: What They Are and Why It's Important to Be Educated - Legal Examiner - February 17th, 2020
- Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? - Forbes - February 17th, 2020
- Genetic Secrets of How a Strange Marine Animal Produces Unlimited Eggs and Sperm Over Its Lifetime - SciTechDaily - February 15th, 2020
- Stem Cells Market Report by Manufacturers, Regions, Type and Application Forecast 2020-2025, Trends, Proportions, Share and SWOT. - Chronicle 99 - February 15th, 2020
- Embryonic Stem Cells - February 11th, 2020
- 3. Embryonic Stem Cells | Stem Cells and the Future of ... - February 5th, 2020
- Embryonic Stem Cell Fact Sheet - February 5th, 2020
- Embryonic Stem Cell Research Pros and Cons - Biology Wise - February 5th, 2020
- Early onset Parkinsons might begin in the womb: Prevention a possibility - The New Daily - February 1st, 2020
- How does the embryo make all its parts at just the right moments? - Knowable Magazine - January 31st, 2020
- Biobanking Market to Witness an Outstanding Growth During 2019-2030 :Thermo Fisher Scientific Inc., PHC Holdings Corporation, QIAGEN NV - Media... - January 31st, 2020
- What are Progenitor Cells? Exploring Neural, Myeloid and Hematopoietic Progenitor Cells - Technology Networks - January 29th, 2020
- Lab-Grown Heart Muscles Have Been Transplanted Into a Human For The First Time - ScienceAlert - January 29th, 2020
- Antibodies recognizing the C terminus of PP2A catalytic subunit are unsuitable for evaluating PP2A activity and holoenzyme composition - Science - January 29th, 2020
- Comprehensive Research on Human Embryonic Stem Cells (HESC) Market Report 2026 | Astellas Pharma Inc/ Ocata Therapeutics ,STEMCELL Technologies... - January 26th, 2020
- Stem Cell Therapy Market Anticipated to Grow at a Significant Pace by 2020 - The Trusted Chronicle - January 26th, 2020
- What I Learned About Marriage as a Survivor of Abuse - SWAAY - January 26th, 2020
- Stem Cell Therapy Market Current Trends and Future Growth Dagoretti News - Dagoretti News - January 22nd, 2020
- Memphis Meats raises $161m to build its cell-based meat platform: 'We have a pretty clear path to bringing prices down to cost parity' -... - January 22nd, 2020
- Stem Cell Assay Market Predicted to Accelerate the Growth by 2017-2025 Dagoretti News - Dagoretti News - January 17th, 2020
- Team builds the 1st living robots - EarthSky - January 17th, 2020
- Team Builds the First Living Robots - Newswise - January 17th, 2020
- The 'xenobot' is the worlds newest robot and it's made from living animal cells - The Loop - January 17th, 2020
- Scientists Have Built The First-Ever Robots Constructed Entirely Out of Living Cells - ScienceAlert - January 14th, 2020
- Scientists Assemble Frog Stem Cells Into First 'Living Machines' - Smithsonian.com - January 13th, 2020